China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical tri
BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website of China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 Injection. This is the first personalized neoantigen vaccine & mRNA editing product approved by the NMPA to enter clinical stage.
Adoptive cell therapy for cancer treatment Market Sales and Market Shares of Major Suppliers 2017-20
"Adoptive cell therapy for cancer treatment Market: Global Industry Analysis and Opportunity Assessment 2017-2027"
More Cancer Mutations, Better Immunotherapy Outcomes
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Scientists Discover FGL1, A Key Blocker of Immune Response Against Certain Cancers
A protein called FGL1 is a major inhibitory signal that blocks the immune system from fighting certain cancers, a team led by researchers at Yale Cancer Center (YCC) found.
Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma
The efficacy and safety observed with the CAR T-cell product bb21217 could help physicians get patients with heavily pretreated relapsed/refractory multiple myeloma on the path towards a cure, according to Nina Shah, MD.
Phase 3 Trial Explores Cabometyx-Tecentriq Combo Therapy in Advanced Liver Cancer
A pivotal Phase 3 clinical trial testing a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) versus standard care of Nevaxar (sorafenib) in previously untreated patients with advanced hepatocellular carcinoma (HCC) — the most common ty
Cancer Death Rates on the Decline, 2019 Cancer Stats Report Shows
Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on canc
A 1-2 Approach to Mobilizing Immune Response Against ‘Lingering’ Kidney Cancer Cells
Clinical study to evaluate mobilizing a patients’ immune response against cancer cells that remain in the body after surgery
Top 10 Immuno-Oncology Stories of 2018
Immuno-Oncology News brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events related to cancer immunology throughout 2018.
Five Things To Look Out For In Cancer Research In 2019
2018 was a remarkable year for cancer research, with great strides made in diagnosing and treating various types of cancer as well as important breakthroughs looking at the health of cancer survivors. What can we expect to see from cancer research in 2019
History of immunology and tumor immunity1893
Use of live bacteria and bacterial lysates to treat tumors-"Coley's Toxins" (William B. Coley).
History of immunology and tumor immunity1957
Thomas and Burnet first proposed the theory of cancer immunosurveillance.
History of immunology and tumor immunity1958
Discovery of human leukocyte antigens (Jean Dausset and others).
History of immunology and tumor immunity1959
Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter).
History of immunology and tumor immunity1973
Dendritic Cells first described by Ralph M. Steinman.
History of immunology and tumor immunity1974
T-cell restriction to MHC (Rolf Zinkernagel and (Peter C. Doherty)
History of immunology and tumor immunity1975
Generation of monoclonal antibodies (Georges Köhler) and (César Milstein).
History of immunology and tumor immunity1976
Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)
History of immunology and tumor immunity1983
Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack) and (John Kappler) (James Allison)
History of immunology and tumor immunity1985
Large doses of IL-2 were shown to be effective when administered to patients with established, metastatic cancers by enhancing T-cell production.
History of immunology and tumor immunity1988
Autologous TIL used to treat melanoma patients.
History of immunology and tumor immunity1992
Honjo first identified PD-1 as an inducible gene on activated T-lymphocytes, and this discovery significantly contributed to the establishment of cancer immunotherapy principle by PD-1 blockade.
History of immunology and tumor immunity1995
First Dendritic cell vaccine trial reported by Mukherji et al.
History of immunology and tumor immunity1996
James Allison was the first to show that antibody blockade of CTLA-4 could lead to enhanced anti-tumor immune responses and tumor rejection.
History of immunology and tumor immunity1997
First antibody treatment approved for use by the FDA(rituximab).
History of immunology and tumor immunity2010
The first autologous cell-based cancer vaccine, PROVENGE, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.
History of immunology and tumor immunity2011
First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA.
History of immunology and tumor immunity2014
A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma.
History of immunology and tumor immunity2017
The first autologous CAR T-cell therapy Kymriah is approved for the treatment of pediatric B-ALL.
Two independent clinical studies provided solid evidence that neoantigen-based cancer vaccines could be developed to elicit potent neoantigen-specific T ce
In personalized tumor immunotherapy, appropriate drug forms are selected for clinical treatment according to different indications based on the identification and screening of tumor-specific neoantigens. We developed Likang Neoantigen Epitope Analysis (LNEA) platform and dendritic cell (DC) loaded with tumor-specific neoantigens, neoantigen specific T cell (Neo-T), transgenic T cell (TCR-T), and etc. which may enable us to predict the presence of unique neoantigens in tumor cells of patients, and based on multiple product lines, gradually promote individualized tumor immunotherapy to clinical application.